Logo

Samuel Zalipsky, John Berriman

May 31, 2007
Premium
Intradigm has named Samuel Zalipsky as its vice president of technology development.
 
Intradigm said he will be responsible for overseeing the company’s continued development of its nanoparticle-based RNAi delivery technology, as well as novel RNAi drug formulations. Salipsky will also handle Intradigm’s new technology development and in-licensing efforts.
 
Zalipsky has previously held positions with Alza, Sequus Pharmaceuticals, and Enzon.
 
 
Pronota, a Belgian predictive biomarker firm, has named John Berriman as its chairman.
 
Berriman was previously a director of Alnylam Pharmaceuticals.

Filed under

Gene Silencing/Gene Editing
RNAi
Breaking News
The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.